High-Dose Sildenafil Citrate for Selective Serotonin Reuptake Inhibitor–Associated Ejaculatory Delay: Open Clinical Trial
J Clin Psychiatry 2003;64:721-725
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Selective serotonin reuptake
inhibitor (SSRI)-induced ejaculatory delay is a common problem
that has no treatment with established efficacy. Sildenafil
citrate is effective for erectile dysfunction and appears to be
safe at doses up to 200 mg.
Method: We enrolled men who were in remission
from depression according to DSM-IV criteria and who reported
that they had developed new-onset ejaculatory delay in the
setting of SSRI treatment. Enrolled patients were instructed to
use 25 mg of sildenafil 1 hour prior to sexual activity on at
least 2 occasions. If this was not effective for the ejaculatory
delay, they were instructed to increase the dose progressively up
to a maximum of 200 mg. We compared baseline sexual functioning
to 2 phases of open treatment: low-dose phase (sildenafil 25-100
mg) and high-dose phase (sildenafil 150-200 mg). The primary
outcome measure was a modified, self-report Clinical Global
Impressions (CGI) scale that was specific for erectile (CGI-EF)
and ejaculatory (CGI-EJF) aspects of sexual function.
Results: Twenty-one men (mean age = 56 years)
with major depressive disorder (MDD) in remission and
SSRI-associated ejaculatory delay enrolled in the study and
received sildenafil. At baseline, 14 of 21(67%) had comorbid
erectile dysfunction. At the low-dose phase follow-up assessment,
12 of 14 achieved full erectile dysfunction remission, and 4 of
21 achieved ejaculatory delay remission. Sixteen patients with
persistent ejaculatory delay were eligible for the high-dose
phase: 5 withdrew from the study, 4 increased to a maximum dose
of 150 mg, and 6 increased to a maximum dose of 200 mg. The 1
patient who had clinically significant erectile dysfunction and
ejaculatory delay reported improvement of both conditions after
the high-dose phase. Of the 10 patients who had ejaculatory delay
without significant erectile dysfunction and who chose to take
high-dose sildenafil, 9 reported a significant clinical
improvement in ejaculatory delay (CGI-EJF improvement score of 1
or 2) and 7 achieved full remission (CGI-EJF severity score of 1
or 2 and CGI-EJF improvement score of 1 or 2).
Conclusion: In this open clinical trial with men
who had SSRI-induced ejaculatory delay, high-dose sildenafil
appeared to be effective in reducing ejaculatory latency.